Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05434247
Registration number
NCT05434247
Ethics application status
Date submitted
19/03/2022
Date registered
27/06/2022
Date last updated
27/06/2022
Titles & IDs
Public title
Comparing the Diagnostic Adequacy of 25-gauge Fork-tip, Franseen and Reverse-bevel Type Needles in Endoscopic Ultrasound Guided Tissue Acquisition
Query!
Scientific title
A Prospective Randomized Study Comparing the Diagnostic Adequacy of 25-gauge Fork-tip, Franseen and Reverse-bevel Type Needles in Endoscopic Ultrasound Guided Tissue Acquisition
Query!
Secondary ID [1]
0
0
LNR/QMS/44303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Biopsy, Needle
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Needle choice
Other: Reverse-bevel ProCore™ - Historical comparator group of biopsies taken using Echo Tip® HD ProCore™ (Wilson-Cook Medical Inc., Winston-Salem, NC, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
Experimental: Fork-tip SharkCore™ - Experimental group of biopsies using SharkCore™ (Medtronic Inc., Sunnyvale, CA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
Experimental: Franseen Acquire™ - Experimental group of biopsies using Acquire™ (Boston Scientific, Marlborough, MA, United States) biopsy needle. Slow pull stylet technique with rapid on site evaluation in all cases.
Treatment: Devices: Needle choice
The type of needle use was the only intervention
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Diagnostic yield
Query!
Assessment method [1]
0
0
The percentage of lesions sampled for which a tissue diagnosis was obtained
Query!
Timepoint [1]
0
0
At study completion, approximately 1 year after final subject enrolled
Query!
Secondary outcome [1]
0
0
Number of needle passes
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
At study completion, approximately 1 year after final subject enrolled
Query!
Secondary outcome [2]
0
0
Sample bloodiness
Query!
Assessment method [2]
0
0
A subjective assessment of the amount of blood seen on histopathological specimens (1 = no interference with interpretation, 2 = interference with interpretation but diagnosis can still be made, 3 = excessive blood makes assessment impossible)
Query!
Timepoint [2]
0
0
At study completion, approximately 1 year after final subject enrolled
Query!
Secondary outcome [3]
0
0
Target tissue cellularity
Query!
Assessment method [3]
0
0
Subjective assessment by histopathologist of the cellularity of the sample (consisting of cells from the target lesion) - low, medium or high.
Query!
Timepoint [3]
0
0
At study completion, approximately 1 year after final subject enrolled
Query!
Eligibility
Key inclusion criteria
- Any solid tissue biopsy performed at the time of endoscopic ultrasound
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Fluid samples were excluded.
- Cases where biopsy was not deemed necessary by the proceduralist based on
endosonographic findings
- Cases where biopsy was deemed unsafe
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
178
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4102 - Brisbane
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Princess Alexandra Hospital, Brisbane, Australia
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and fine needle biopsy
(EUS-FNB) are well established techniques for the acquisition of tissue to classify a number
of lesions of the gastrointestinal tract and surrounding organs. These include pancreatic,
lymphoid, subepithelial and other abdominal lesions. Historically, FNA was the sole available
modality used to obtain cytological samples for analysis. The major shortcoming of this
technique is the lack of a histological tissue core.
In recent years attention has turned to optimizing needle design to improve sample quality.
New needles have been developed which aim to obtain a core of tissue with preserved
architecture.
These needles include the first generation Reverse-bevel Echo Tip® HD ProCore™ (Wilson-Cook
Medical Inc., Winston-Salem, NC, United States), and the second generation Fork-tip
SharkCore™ (Medtronic Inc., Sunnyvale, CA, United States) and Franseen Acquire™ (Boston
Scientific, Marlborough, MA, United States).
Currently there are a paucity of studies comparing the performance of these needles, and only
two of these are prospective randomized controlled trials. Real world performance of these
needles has seldom been reported, with only one RCT including non-pancreatic masses in their
analysis.
The investigators hypothesize that second generation needles have equivalent or better
diagnostic performance than the prior first-generation needle.
To test this, the investigators aim to conduct a prospective randomized controlled study
comparing the performance of Fork-tip and Franseen needles for the sampling of pancreatic,
subepithelial, lymphoid and other abdominal or mediastinal lesions. They also aim to include
a retrospective control arm of consecutive cases using the first-generation Reverse-bevel
needle.
The investigatora aim to assess the diagnostic yield of each needle, as well as number of
needle passes used, and specimen quality.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05434247
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Alexander Huelsen, MD
Query!
Address
0
0
QLD Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05434247
Download to PDF